BPC-157

BPC-157, also known as Body Protection Compound-15, PL 14736, PL-10, Bepecin, or pentadecapeptide BPC 157, is a research peptide classified within the tissue repair and healing category. This synthetic peptide has garnered significant attention in laboratory studies for its potential mechanisms in promoting tissue regeneration and repair processes. The compound is thought to promote healing through modulation of growth factors and cytokines involved in tissue repair pathways. Research indicates that BPC-157 enhances angiogenesis, the formation of new blood vessels, which supports tissue regeneration in experimental models. The peptide also demonstrates properties related to cellular membrane stabilisation and protection against oxidative stress in laboratory conditions. Studies suggest that BPC-157 may influence the nitric oxide system, contributing to its observed anti-inflammatory effects in research settings. Primary research effects documented in the literature include accelerated wound healing, reduced inflammation, promotion of tendon and ligament repair, gastric mucosa protection, and enhanced angiogenesis in various experimental models. The current evidence base for BPC-157 remains limited, with only three published human studies encompassing fewer than 30 subjects total. A 2025 intravenous safety study involving two patients reported no adverse effects, whilst a 2024 pilot study in interstitial cystitis with 12 women showed 80-100% symptom resolution. The compound currently holds FDA Category 2 classification, though regulatory announcements indicate an expected reversion to Category 1 status by February 2026. Researchers investigating tissue repair mechanisms, wound healing pathways, and angiogenesis processes may find BPC-157 relevant to their laboratory studies. The peptide's multifaceted approach to tissue protection and repair makes it a compound of interest in various research applications focused on regenerative processes.